Author:
García-Mayor Ricardo V. G.,Páramo C.,Cano R. Luna,Méndez L. F. Pérez,Galofré J. C.,Andrade A.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference35 articles.
1. Laurberg P., Hansen P.E., Iversen E., Jensen S.E., Weete J. Goitre size and outcome of medical treatment of Graves’ disease. Acta Endocrinol. (Copenh.) 111: 39, 1986.
2. Takamatsu J., Kuma K., Mozai T. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves’ disease. J. Clin. Endocrinol. Metab. 62: 980, 1986.
3. Wilson R., McKillop J.H., Henderson N., Pearson D.W., Thomson J.A. The ability of the serum thyrotrophin receptor antibody (TRab) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves’ disease. Clin. Endocrinol. (Oxf.) 25: 151, 1986.
4. Winsa A., Dahlberg P.A., Jansson R., Agren H., Karlsson F.A. Factors influencing the outcome of thyrostatic drug therapy in Graves’ disease. Acta Endocrinol. (Copenh.) 122: 622, 1990.
5. Hedley A.J., Young R.E., Jones S.J., Alexander W.D., Bewsher P.D., Scottish automated follow-up register group. Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: long-term follow-up of 434 patients. Clin. Endocrinol. (Oxf.) 31: 209, 1989.
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献